InvestorsHub Logo
Followers 211
Posts 32318
Boards Moderated 1
Alias Born 06/30/2009

Re: None

Thursday, 02/22/2018 4:39:24 PM

Thursday, February 22, 2018 4:39:24 PM

Post# of 146291
"On January 27, 2018, the Company’s Chief Executive Officer, Dr. Eugene Seymour, resigned as the Chief Executive Officer and as a Director of the Company to allow a successor with pharmaceutical experience to serve in this capacity. Subject to the entry into a Severance Agreement, Dr. Seymour will assume the role of Chief Executive Officer Emeritus. The Board of Directors previously commenced a search for a permanent replacement for Dr. Seymour, which is ongoing. The Board of Directors has appointed Dr. Anil Diwan, the Company’s President, as Interim Chief Executive Officer."


They had more than three weeks between his resignation and the Subsequent Event filing to slap together a severance agreement. That COULD HAVE been done. I don't expect it to be cheap.
It sounds like they are making the Chief Executive Officer Emeritus title subject to his acceptance of some other terms in his severance agreement. Such things aren't usually bestowed upon an individual in return for a concession.
"The Board of Directors previously commenced a search for a permanent replacement for Dr. Seymour". Previous to his resignation?

Is Dr. S going quietly? Or is he being given a not-so-gentle shove?
The people here who have exchanged missives with him many times in the past haven't forwarded any of his comments in quite a while.

But can it core A apple?
Yes Ralph, of course it can core A apple.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News